Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition

Author: McKillop D.   Guy S. P.   Spence M. P.   Kendrew J.   Kemp J. V.   Bushby N.   Wood P. G.   Barnett S.   Hutchison M.  

Publisher: Informa Healthcare

ISSN: 1366-5928

Source: Xenobiotica, Vol.36, Iss.1, 2006-01, pp. : 29-39

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content